Elderly woman applying moisturizing lotion cream on hand palm, easing aches. Senior old lady experiencing severe arthritis rheumatics pains, massaging, warming up arm. Close up, copy space, background

A senior woman's hands (© Evrymmnt - stock.adobe.com)

WEST LAFAYETTE, Ind. — Osteoporosis is a particularly nasty ailment that results in one’s bones becoming weak, brittle, and easily broken. Now, researchers from Purdue University have created a new form of a pre-existing drug already being used to treat osteoporosis. They say this newer version may represent a fresh treatment option with less side-effects for people dealing with calcium-related disorders.

All humans require the hormone called calcitonin in order to maintain normal calcium stability. Osteoporosis patients usually don’t have enough calcitonin, so they’re prescribed calcitonin as a treatment. When taken regularly, this drug blocks bone resorption, ultimately leading to increased bone mass.

This new form of human calcitonin is more stable than earlier varieties of the peptide drug. It was invented when the team at Purdue created a prodrug form of the peptide hormone. These changes should increase the drug’s effectiveness against osteoporosis and related problems considerably.

‘Our approach will increase therapeutic potential of human calcitonin’

All of that sounds great, but human calcitonin ends up undergoing fibrillation when placed in a water solution. This leads to reduced therapeutic efficiency. To overcome the problem, many osteoporosis patients have been prescribed salmon calcitonin instead. Salmon calcitonin does not fibrillate as much as human calcitonin, but it also isn’t nearly as helpful and offers more harmful side-effects.

“The technology can help make these calcitonin drugs safer and more effective,” says professor of physical and industrial pharmacy Elizabeth Topp in a university release. “Our approach will increase the therapeutic potential of human calcitonin, promising a more effective option to replace salmon calcitonin for osteoporosis and related disorders.”

To decrease the potential for fibrillation and increase the therapeutic benefits of human calcitonin, researchers added a phosphate group to specific amino acid residues.

“Many promising new peptide drugs tend to form fibrils,” Topp concludes. “This technology provides a way to stabilize them in a reversible way so that the stabilizing modification comes off when the drug is given to the patient.”

The study is published in Biophysical Journal.

About John Anderer

Born blue in the face, John has been writing professionally for over a decade and covering the latest scientific research for StudyFinds since 2019. His work has been featured by Business Insider, Eat This Not That!, MSN, Ladders, and Yahoo!

Studies and abstracts can be confusing and awkwardly worded. He prides himself on making such content easy to read, understand, and apply to one’s everyday life.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

Chris Melore

Editor

Sophia Naughton

Associate Editor